The NMDAR ‘glycine modulation site’ is a direct or indirect common target for D-serine, D-cycloserine, glycine transport protein 1 inhibitors and D-amino acid oxidase inhibitors, which are promising agents for improving cognitive impairment in schizophrenia33,34. This evidence concerns the gene DAO and Cognitive impairment.